ReviewClinical ophthalmology (Auckland, N.Z.)2014
Latanoprost in the treatment of glaucoma.
Review in Clinical ophthalmology (Auckland, N.Z.), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06000280 (Evaluation of Macular Thickness in Patients With Glaucoma in Use of Topical Prostaglandin Analogue Undergoing Trabeculectomy With Mitomycin C), which is not on this map. Cited by 66 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Evaluation of Macular Thickness in Patients With Glaucoma in Use of Topical Prostaglandin Analogue Undergoing Trabeculectomy With Mitomycin C
Who cites it
66 citing papers in PubMed, 118 citations in OpenAlex.
- Comparison of Preservative-Free and Preserved Latanoprost in Primary Open-Angle Glaucoma: A Randomized Cross-Over Study.Korean journal of ophthalmology : KJO · 2026Trial
- Fifteen-Month Outcomes of Preservative-Free Latanoprost Cationic Emulsion in Open-Angle Glaucoma and Ocular Hypertension: Phase III Open-Label Extension of a Randomized Trial.Clinical ophthalmology (Auckland, N.Z.) · 2025Trial
- Omidenepag Isopropyl 0.002% versus Latanoprost 0.005% in Open-Angle Glaucoma/Ocular Hypertension: The Randomized Phase III PEONY Trial.Clinical ophthalmology (Auckland, N.Z.) · 2024Trial
- Preservative-Free versus Benzalkonium Chloride-Preserved Latanoprost Ophthalmic Solution in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension: A Phase 3 US Clinical Trial.Clinical ophthalmology (Auckland, N.Z.) · 2023Trial
- Phase 2b, Randomized, 3-Month, Dose-Finding Study of Sepetaprost in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension: The ANGEL Study.Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics · 2022Trial
- The RELIEF study: Tolerability and efficacy of preservative-free latanoprost in the treatment of glaucoma or ocular hypertension.European journal of ophthalmology · 2019Trial
- Latanoprostene Bunod 0.024% in Subjects With Open-angle Glaucoma or Ocular Hypertension: Pooled Phase 3 Study Findings.Journal of glaucoma · 2018Trial
- A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of 2 and 4 Weeks of Twice-Daily Ocular Trabodenoson in Adults with Ocular Hypertension or Primary Open-Angle Glaucoma.Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics · 2016Trial
- Long-term Safety and Efficacy of Latanoprostene Bunod 0.024% in Japanese Subjects with Open-Angle Glaucoma or Ocular Hypertension: The JUPITER Study.Advances in therapy · 2016Trial
- Concomitant limaprost use and intraocular pressure response to latanoprost in normal-tension glaucoma: A retrospective cohort study.Medicine · 2026Article
- Latanoprost Acid-Brimonidine, a New Amide Prodrug for Glaucoma Management Based on the Concept of Sustained Release.Molecules (Basel, Switzerland) · 2026Article
- Promising Glaucoma Medication: A Comprehensive Translational Evaluation.Pharmaceutics · 2026Article
- Preservative-free latanoprost induces meibomian gland dysfunction through inflammatory and oxidative stress pathways.BMC pharmacology & toxicology · 2026Article
- Engineering Drug-Eluting Ocular Bioadhesive "OcuTAPE" via Tannic Acid-Mediated Nanoparticle Bridging.Advanced functional materials · 2026Article
- Development of a conjunctival contact-type drug delivery device for latanoprost using hyaluronic acid.Drug delivery · 2025Article
- Ketorolac, melatonin and latanoprost tri-loaded PLGA microspheres for neuroprotection in glaucoma.Drug delivery · 2025Article
- Clinical Benefits of Preservative-Free Treatment for Glaucoma with a Focus on Preservative-Free Latanoprost.Ophthalmology and therapy · 2025Review
- The Effect of Preoperative Use of High- vs. Low-PAP-Inducing-Potential FP Agonists on the Surgical Outcomes of Trabeculectomy and AGV Implantation.Journal of clinical medicine · 2025Article
- The Investigation of Latanoprost's Effects on the Intraocular Pressure of Healthy Male guinea Pigs Under Light and Dark Regimes.Veterinary medicine and science · 2025Article
- Self-assembled latanoprost loaded soluplus nanomicelles as an ophthalmic drug delivery system for the management of glaucoma.Scientific reports · 2024Article
6 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prostaglandins are approved by the European Glaucoma Society guidelines as first-line treatment for glaucoma. This review focuses on latanoprost, an ester prodrug of prostaglandin (PG) F2α, which was the first of the currently available topical PGF2α analogs to be launched for glaucoma or ocular hypertension and which still accounts for the majority of prescriptions. It is better absorbed than the parent compound through the cornea, and peak concentration of the active drug is in the aqueous humor 1-2 hours after topical dosing (15-30 ng/mL). Metabolism occurs mainly in the liver. Latanoprost (0.005%) has been very well studied in clinical trials and meta-analyses that show it to be generally as effective as the other PG analogs (bimatoprost, travoprost, and tafluprost) and more effective than timolol, dorzolamide, and brimonidine. Latanoprost has good short- and long-term safety and tolerability profiles. In common with other prostaglandins, it lacks systemic effects, but can cause ocular adverse events such as conjunctival hyperemia, pigmentation of the iris, periocular skin or eyelashes, hypertrichosis, and ocular surface effects or irritation. Latanoprost is significantly better tolerated than either bimatoprost or travoprost. Patients treated with latanoprost have better compliance and persist with therapy longer than those that are given other drugs. An improved formulation of latanoprost without the preservative benzalkonium chloride has recently been developed. It is as effective as conventional latanoprost, has a lower incidence of hyperemia, and can be stored at room temperature. In conclusion, latanoprost has the best efficacy-tolerability ratio of the PG analogs available for glaucoma treatment, and has good compliance and persistence. These factors should be improved further by the recent development of preservative-free latanoprost.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.